Dr. Martens plc (DOCS), the iconic British footwear brand listed on the London Stock Exchange's Main Market, has notified the market of the admission of 94,286 further ordinary shares to trading, issued in connection with the company's employee share schemes. The admission covers shares issued between 1 October 2026 and 31 October 2026, admitted under a block admission arrangement dated 12 December 2024. Following this admission, the total number of ordinary shares in issue stands at 968,121,259. Investors in the FTSE 250 constituent will note the modest but routine increase to the company's share capital.

Key Points

  • Dr. Martens plc (DOCS) — FTSE 250 constituent, listed on the London Stock Exchange Main Market
  • 94,286 new ordinary shares of GBP 0.01 each admitted to trading under the company's employee share schemes
  • Admission period: 1 October 2026 to 31 October 2026; total shares in issue now 968,121,259
  • Investors should watch for further block admissions under the December 2024 arrangement as employee schemes continue

94,286 Dr. Martens Shares Admitted Under December 2024 Block Admission Arrangement

The notification, made in accordance with PRM 1.6.4R, confirms that 94,286 ordinary shares of GBP 0.01 each, carrying ISIN GB00BL6NGV24, have been admitted to trading on the London Stock Exchange Main Market. The shares are described as fully fungible with existing ordinary shares, meaning they carry identical rights and are interchangeable with the company's existing share capital. The admission is made under a block admission arrangement dated 12 December 2024, specifically in connection with Dr. Martens' employee share schemes, a common mechanism used by listed companies to incentivise and retain staff.

Total Dr. Martens Share Capital Reaches 968,121,259 Ordinary Shares Following October Admission

Following this admission, the total number of Dr. Martens ordinary shares in issue rises to 968,121,259. The 94,286 newly admitted shares represent a small incremental addition to the existing capital base, consistent with the routine nature of employee share scheme issuances. No prospectus was required in connection with this admission, as confirmed in the announcement. Investors monitoring dilution levels may note that the increase is modest relative to the overall share count, though cumulative issuances under the block admission arrangement over time could be a factor worth tracking.

Dr. Martens: A FTSE 250 Footwear Brand Operating Across More Than 60 Countries

Dr. Martens is a British heritage footwear brand founded in Northamptonshire, England, whose iconic 1460 boot first rolled off the production line on 1 April 1960. The company operates in more than 60 countries, employs around 3,600 people, and sells through Direct-to-Consumer retail, ecommerce, and wholesale channels. Its product range spans original silhouettes — including the 1460 boot, 1461 shoe, 2976 Chelsea boot, and Adrian loafer — alongside newer franchises and accessories. The company continues to manufacture 'Made in England' footwear at its original Northamptonshire factory alongside production sites across Asia.